Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 8;43(9):1677-1696.e15.
doi: 10.1016/j.ccell.2025.06.021. Epub 2025 Jul 24.

Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer

Affiliations

Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer

Yijuan Zhang et al. Cancer Cell. .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) tumors are glutamine deficient, and both tumor cells and cancer-associated fibroblasts (CAFs) rely on this amino acid to maintain fitness and induce macropinocytosis as an adaptive response. CAFs play a critical role in sculpting the tumor microenvironment, yet how adaptations to metabolic stress impact the stromal architecture remains elusive. In this study, we find that macropinocytosis sustains the myCAF phenotype under glutamine limitation by preventing inflammatory reprogramming. Our data demonstrate that metabolic stress induces an intrinsic inflammatory CAF (iCAF) program through MEK-ERK signaling. We find that blocking macropinocytosis in vivo promotes myCAF-to-iCAF transitions, remodeling the tumor stroma. Importantly, stromal remodeling driven by macropinocytosis inhibition-including iCAF enrichment, collagen reduction, immune cell infiltration, and vascular expansion-sensitizes PDAC tumors to immunotherapy and chemotherapy. Our findings reveal that inhibiting macropinocytosis promotes an inflammatory, less fibrotic tumor microenvironment that can be leveraged to improve therapeutic responses in PDAC.

Keywords: CAF heterogeneity; chemotherapy; drug delivery; immunotherapy; macropinocytosis; metabolic stress; pancreatic cancer; plasticity; stromal architecture; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests C.C. is an inventor on a U.S. patent titled “Cancer diagnostics, therapeutics, and drug discovery associated with macropinocytosis,” patent number: US-11209420-B2.

Update of

References

    1. Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, et al. (2020). A framework for advancing our understanding of cancer-associated fibroblasts. Nature reviews. Cancer 20, 174–186. 10.1038/s41568-019-0238-1. - DOI - PMC - PubMed
    1. LeBleu VS, and Kalluri R (2018). A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech 11. ARTN dmm029447 10.1242/dmm.029447. - DOI - PMC - PubMed
    1. Caligiuri G, and Tuveson DA (2023). Activated fibroblasts in cancer: Perspectives and challenges. Cancer cell 41, 434–449. 10.1016/j.ccell.2023.02.015. - DOI - PMC - PubMed
    1. Biffi G, and Tuveson DA (2021). Diversity and Biology of Cancer-Associated Fibroblasts. Physiological reviews 101, 147–176. 10.1152/physrev.00048.2019. - DOI - PMC - PubMed
    1. Sherman MH, and Beatty GL (2023). Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Annual review of pathology 18, 123–148. 10.1146/annurev-pathmechdis-031621-024600. - DOI - PMC - PubMed

LinkOut - more resources